<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02565901</url>
  </required_header>
  <id_info>
    <org_study_id>9388</org_study_id>
    <secondary_id>NCI-2015-01478</secondary_id>
    <secondary_id>9388</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>P50CA097186</secondary_id>
    <secondary_id>RG1715104</secondary_id>
    <nct_id>NCT02565901</nct_id>
  </id_info>
  <brief_title>Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer: (Rapamycin Inhibition of DDSP [RID])</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This partially randomized phase I/II trial studies the side effects and how well sirolimus&#xD;
      works when given together with docetaxel and carboplatin in treating patients with&#xD;
      castration-resistant prostate cancer that has spread to other places in the body&#xD;
      (metastatic). Biological therapies, such as sirolimus, use substances made from living&#xD;
      organisms that may stimulate or suppress the immune system in different ways and stop tumor&#xD;
      cells from growing. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells, by stopping&#xD;
      them from dividing, or by stopping them from spreading. Giving sirolimus together with&#xD;
      docetaxel and carboplatin may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To define the recommended phase 2 dose (RP2D) of sirolimus combined with docetaxel and&#xD;
      carboplatin in the treatment of metastatic castration resistant prostate cancer (CRPC).&#xD;
      (Phase I)&#xD;
&#xD;
      II. To assess the effectiveness of sirolimus in suppressing the induction of the&#xD;
      deoxyribonucleic acid (DNA) damage secretory component WNT16B in tumor stroma following&#xD;
      docetaxel and carboplatin. (Phase II)&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To assess maximal prostate-specific antigen (PSA) response to sirolimus combined with&#xD;
      docetaxel and carboplatin. (Phase I)&#xD;
&#xD;
      II. To assess PSA response duration to sirolimus combined with docetaxel and carboplatin.&#xD;
      (Phase I)&#xD;
&#xD;
      III. To assess response of measurable disease. (Phase I)&#xD;
&#xD;
      IV. To assess time to progression of bone lesions or measurable disease (Response Evaluation&#xD;
      Criteria in Solid Tumors [RECIST] 1.1). (Phase I)&#xD;
&#xD;
      V. To assess effect of sirolimus with docetaxel and carboplatin on DNA damage surrogates in&#xD;
      cancer associated stroma compared to untreated and docetaxel and carboplatin treated stroma.&#xD;
      (Phase I)&#xD;
&#xD;
      VI. To assess maximal PSA response to sirolimus combined with docetaxel and carboplatin.&#xD;
      (Phase II)&#xD;
&#xD;
      VII. To assess PSA response duration to sirolimus combined with docetaxel and carboplatin.&#xD;
      (Phase II)&#xD;
&#xD;
      VIII. To assess response of measurable disease (RECIST 1.1). (Phase II)&#xD;
&#xD;
      IX. To assess time to progression of bone lesions or measurable disease (RECIST 1.1). (Phase&#xD;
      II)&#xD;
&#xD;
      X. To assess toxicity of the RP2D dose of sirolimus with docetaxel and carboplatin. (Phase&#xD;
      II)&#xD;
&#xD;
      XI. To determine the effect of docetaxel and carboplatin therapy on the DNA damage secretory&#xD;
      program (DDSP) in serum. (Phase II)&#xD;
&#xD;
      XII. To determine response to sirolimus, docetaxel and carboplatin in tumors with mutation of&#xD;
      DNA repair pathway genes (breast cancer gene 2 [BRCA2], ataxia telangiectasia mutated [ATM]&#xD;
      and other Fanconi anemia complementation groups [FANC] pathway members). (Phase II)&#xD;
&#xD;
      XIII. To correlate the presence of DNA repair pathway mutations in circulating tumor cells&#xD;
      (CTC) and circulating tumor DNA (ctDNA) with tumor biopsy and correlate changes in CTC number&#xD;
      and ctDNA mutation levels with clinical responses. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a phase I, dose de-escalation study of sirolimus followed by a phase II&#xD;
      study.&#xD;
&#xD;
      PHASE I: Patients receive sirolimus orally (PO) on day -2*. Patients also receive docetaxel&#xD;
      intravenously (IV) over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1.&#xD;
      Treatment repeats every 21 days for 10 cycles in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      PHASE II: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on&#xD;
      day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive&#xD;
      sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over&#xD;
      30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days&#xD;
      for 10 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      * NOTE: Patients receive sirolimus 2 days prior to chemotherapy day 1 (there is no day 0).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to insufficient funding&#xD;
  </why_stopped>
  <start_date type="Actual">February 29, 2016</start_date>
  <completion_date type="Actual">June 16, 2020</completion_date>
  <primary_completion_date type="Actual">June 16, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Deoxyribonucleic Acid (DNA) Damage Secretory Program Induction (DDSP) (Phase II)</measure>
    <time_frame>Baseline up to day 21 after starting treatment</time_frame>
    <description>Will be determined by the level of genetic expression of WNT16, IL6, or SFRP2 in tissue after chemotherapy (carboplatin/docetaxel) compared to background/baseline measurement. The primary metric of DDSP induction will be quantitative reverse transcription-polymerase chain reaction, which is quantitative, but in the event of ribonucleic acid degradation in sample processing, the alternative measure will be immunohistochemistry (0-2 scale of expression).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Phases I and II)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Safety will be assessed through summaries of adverse events, vital signs, physical examinations, and clinical laboratory test data. Adverse events will then be quantified via CTCAE 4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Reduction in Prostate Specific Antigen According to the Prostate Cancer Working Group 2 (PCWG2) Criteria (Phases I and II)</measure>
    <time_frame>Baseline to up to 3 years</time_frame>
    <description>PSA decline from the level at registration will be quantified for each patient and proportion of patients with PSA decline divided by the total number of patients enrolled in study will be described.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Castration-Resistant Prostate Carcinoma</condition>
  <condition>Metastatic Prostate Carcinoma</condition>
  <condition>Stage IV Prostate Cancer AJCC v7</condition>
  <condition>Metastatic Malignant Neoplasm in the Bone</condition>
  <arm_group>
    <arm_group_label>Arm I (sirolimus, docetaxel, carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (sirolimus, docetaxel, carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (sirolimus, docetaxel, carboplatin)</arm_group_label>
    <arm_group_label>Arm II (sirolimus, docetaxel, carboplatin)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (sirolimus, docetaxel, carboplatin)</arm_group_label>
    <arm_group_label>Arm II (sirolimus, docetaxel, carboplatin)</arm_group_label>
    <other_name>Docecad</other_name>
    <other_name>RP56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Taxotere Injection Concentrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (sirolimus, docetaxel, carboplatin)</arm_group_label>
    <arm_group_label>Arm II (sirolimus, docetaxel, carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (sirolimus, docetaxel, carboplatin)</arm_group_label>
    <arm_group_label>Arm II (sirolimus, docetaxel, carboplatin)</arm_group_label>
    <other_name>AY 22989</other_name>
    <other_name>RAPA</other_name>
    <other_name>Rapamune</other_name>
    <other_name>Rapamycin</other_name>
    <other_name>SILA 9268A</other_name>
    <other_name>WY-090217</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form (ICF) providing agreement to adhere to the dosing&#xD;
             schedule, report for all trial visits and authorization, use and release of health and&#xD;
             research trial information&#xD;
&#xD;
          -  Histologically or cytologically confirmed carcinoma of the prostate (excluding&#xD;
             neuroendocrine differentiation or squamous cell histology)&#xD;
&#xD;
          -  Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone&#xD;
             (GnRH) analogues, antagonists or orchiectomy; patients who have not had an orchiectomy&#xD;
             must be maintained on effective GnRH analogue/antagonist therapy&#xD;
&#xD;
          -  Castration resistant prostate cancer as defined by serum testosterone &lt; 50 ng/ml and&#xD;
             at least one of the following:&#xD;
&#xD;
               -  PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions&#xD;
                  at least 1 week apart&#xD;
&#xD;
               -  Evaluable disease progression by modified RECIST 1.1&#xD;
&#xD;
               -  Progression of metastatic bone disease on bone scan with &gt; 2 new lesions&#xD;
&#xD;
          -  Prior therapy with abiraterone, enzalutamide and/or docetaxel; if a patient has not&#xD;
             received docetaxel or cabazitaxel chemotherapy, the patient must be informed of this&#xD;
             treatment choice as an alternative; if the patient has received docetaxel or&#xD;
             cabazitaxel chemotherapy or refuses one of both of these therapies, this rationale&#xD;
             must be documented and the patient is then eligible; patient must be offered and made&#xD;
             aware of all Food and Drug Administration (FDA)-approved treatment options; patients&#xD;
             with bone only disease may not have received radium-223&#xD;
&#xD;
          -  The presence of metastatic disease amenable to computed tomography (CT) or ultrasound&#xD;
             guided biopsy; this may include thoracolumbar vertebral bodies, pelvis, femur or&#xD;
             humerus or soft tissue or nodal metastasis amenable to biopsy (excluding lung or&#xD;
             pleural lesions)&#xD;
&#xD;
          -  Agree to participate in biopsy of metastatic lesion during the study at day 21&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of =&lt; 1&#xD;
&#xD;
          -  Life expectancy &gt;= 12 weeks&#xD;
&#xD;
          -  No prior malignancy is allowed except:&#xD;
&#xD;
               -  Adequately treated basal cell or squamous cell skin cancer or&#xD;
&#xD;
               -  In situ carcinoma of any site or&#xD;
&#xD;
               -  Other adequately treated malignancy for which the patient is currently disease&#xD;
                  free for at least one year&#xD;
&#xD;
          -  Patients with any prior chemotherapy regimens are eligible&#xD;
&#xD;
          -  Patients with disease only in the bone may not have received Xofigo/radium 223 to&#xD;
             avoid ongoing DNA damage in bone marrow&#xD;
&#xD;
          -  Patients who are or are not receiving bisphosphonates or denosumab are eligible;&#xD;
             bisphosphonates or denosumab should not be initiated after registration and during&#xD;
             active treatment&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1.5 x 10^9 cells/L (within 14 days prior to registration)&#xD;
&#xD;
          -  Hemoglobin (Hgb) &gt;= 9.0 g/dL (within 14 days prior to registration)&#xD;
&#xD;
          -  Platelets &gt;= 100,000 x 10^9/L (within 14 days prior to registration)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 1.5 x upper&#xD;
             limit of normal (ULN) (within 14 days prior to registration)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN (within 14 days prior to registration)&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 X institutional ULN mg/dL OR estimated glomerular filtration&#xD;
             rate (eGFR) &gt;= 50 mL/min (within 14 days prior to registration)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients currently receiving active therapy for other neoplastic disorders&#xD;
&#xD;
          -  Patients with histologic evidence of small cell carcinoma of the prostate will not be&#xD;
             eligible&#xD;
&#xD;
          -  Patients with disease only in the bone previously treated with radium-223 will not be&#xD;
             eligible&#xD;
&#xD;
          -  Known parenchymal brain metastasis&#xD;
&#xD;
          -  Active or symptomatic viral hepatitis or chronic liver disease&#xD;
&#xD;
          -  Estimated creatinine clearance less than 50 ml/minute&#xD;
&#xD;
          -  Clinically significant heart disease as evidenced by myocardial infarction, or&#xD;
             arterial thrombotic events in the past 6 months, severe or unstable angina, or New&#xD;
             York Heart Association (NYHA) class II-IV heart disease&#xD;
&#xD;
          -  Atrial fibrillation, or other cardiac arrhythmia requiring medical therapy&#xD;
&#xD;
          -  Administration of an investigational therapeutic within 30 days of cycle 1, day -2&#xD;
&#xD;
          -  Patients with dementia/psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements or would prohibit the understanding and/or giving&#xD;
             of informed consent&#xD;
&#xD;
          -  Patients with medical conditions, which, in the opinion of the investigators, would&#xD;
             jeopardize either the patient or the integrity of the data obtained will not be&#xD;
             eligible&#xD;
&#xD;
          -  Any condition which, in the opinion of the investigator, would preclude participation&#xD;
             in this trial&#xD;
&#xD;
          -  Patients on anticoagulation therapy which cannot be held for metastatic biopsies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Montgomery</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 25, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <results_first_submitted>June 8, 2021</results_first_submitted>
  <results_first_submitted_qc>September 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2021</results_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Bruce Montgomery</investigator_full_name>
    <investigator_title>Professor, Medical Oncology Division University of Washington School of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02565901/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Sirolimus, Docetaxel, Carboplatin)</title>
          <description>Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Carboplatin: Given IV&#xD;
Docetaxel: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sirolimus: Given PO</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Sirolimus, Docetaxel, Carboplatin)</title>
          <description>Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Carboplatin: Given IV&#xD;
Docetaxel: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sirolimus: Given PO</description>
        </group>
        <group group_id="P3">
          <title>Phase 1 Group</title>
          <description>Patients treated with docetaxel, carboplatin and sirolimus in the phase 1 component of study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Sirolimus, Docetaxel, Carboplatin)</title>
          <description>Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Carboplatin: Given IV&#xD;
Docetaxel: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sirolimus: Given PO</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Sirolimus, Docetaxel, Carboplatin)</title>
          <description>Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Carboplatin: Given IV&#xD;
Docetaxel: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sirolimus: Given PO</description>
        </group>
        <group group_id="B3">
          <title>Phase 1 Group</title>
          <description>Patients treated with docetaxel, carboplatin and sirolimus in the phase 1 component of study</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="68" upper_limit="82"/>
                    <measurement group_id="B2" value="75" lower_limit="68" upper_limit="82"/>
                    <measurement group_id="B3" value="73" lower_limit="68" upper_limit="82"/>
                    <measurement group_id="B4" value="72" lower_limit="68" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Deoxyribonucleic Acid (DNA) Damage Secretory Program Induction (DDSP) (Phase II)</title>
        <description>Will be determined by the level of genetic expression of WNT16, IL6, or SFRP2 in tissue after chemotherapy (carboplatin/docetaxel) compared to background/baseline measurement. The primary metric of DDSP induction will be quantitative reverse transcription-polymerase chain reaction, which is quantitative, but in the event of ribonucleic acid degradation in sample processing, the alternative measure will be immunohistochemistry (0-2 scale of expression).</description>
        <time_frame>Baseline up to day 21 after starting treatment</time_frame>
        <population>Results do not exist. Because of COVID, the laboratory which would have performed the analysis was shut down for an entire year and inadequate funding exists for data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sirolimus, Docetaxel, Carboplatin)</title>
            <description>Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Carboplatin: Given IV Docetaxel: Given IV Laboratory Biomarker Analysis: Correlative studies Sirolimus: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Sirolimus, Docetaxel, Carboplatin)</title>
            <description>Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Carboplatin: Given IV&#xD;
Docetaxel: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sirolimus: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Deoxyribonucleic Acid (DNA) Damage Secretory Program Induction (DDSP) (Phase II)</title>
          <description>Will be determined by the level of genetic expression of WNT16, IL6, or SFRP2 in tissue after chemotherapy (carboplatin/docetaxel) compared to background/baseline measurement. The primary metric of DDSP induction will be quantitative reverse transcription-polymerase chain reaction, which is quantitative, but in the event of ribonucleic acid degradation in sample processing, the alternative measure will be immunohistochemistry (0-2 scale of expression).</description>
          <population>Results do not exist. Because of COVID, the laboratory which would have performed the analysis was shut down for an entire year and inadequate funding exists for data analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Phases I and II)</title>
        <description>Safety will be assessed through summaries of adverse events, vital signs, physical examinations, and clinical laboratory test data. Adverse events will then be quantified via CTCAE 4.0.</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sirolimus, Docetaxel, Carboplatin)</title>
            <description>Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Carboplatin: Given IV&#xD;
Docetaxel: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sirolimus: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Sirolimus, Docetaxel, Carboplatin)</title>
            <description>Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Carboplatin: Given IV&#xD;
Docetaxel: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sirolimus: Given PO</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Group</title>
            <description>Patients treated with docetaxel, carboplatin and sirolimus in the phase 1 component of study</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Phases I and II)</title>
          <description>Safety will be assessed through summaries of adverse events, vital signs, physical examinations, and clinical laboratory test data. Adverse events will then be quantified via CTCAE 4.0.</description>
          <units>Grade 3 or 4 AE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Reduction in Prostate Specific Antigen According to the Prostate Cancer Working Group 2 (PCWG2) Criteria (Phases I and II)</title>
        <description>PSA decline from the level at registration will be quantified for each patient and proportion of patients with PSA decline divided by the total number of patients enrolled in study will be described.</description>
        <time_frame>Baseline to up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sirolimus, Docetaxel, Carboplatin)</title>
            <description>Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Carboplatin: Given IV&#xD;
Docetaxel: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sirolimus: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Sirolimus, Docetaxel, Carboplatin)</title>
            <description>Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Carboplatin: Given IV&#xD;
Docetaxel: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sirolimus: Given PO</description>
          </group>
          <group group_id="O3">
            <title>Phase 1 Group</title>
            <description>Patients treated with docetaxel, carboplatin and sirolimus in the phase 1 component of study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Reduction in Prostate Specific Antigen According to the Prostate Cancer Working Group 2 (PCWG2) Criteria (Phases I and II)</title>
          <description>PSA decline from the level at registration will be quantified for each patient and proportion of patients with PSA decline divided by the total number of patients enrolled in study will be described.</description>
          <units>Percent with PSA decline</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During time on study to 30 days after last therapy. This was up to 2 years.</time_frame>
      <desc>CTCAE 4.0 definitions of adverse events were used. Patients were evaluated with complete blood counts and comprehensive panels with each cycle and as clinically indicated</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Sirolimus, Docetaxel, Carboplatin)</title>
          <description>Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Carboplatin: Given IV&#xD;
Docetaxel: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sirolimus: Given PO</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Sirolimus, Docetaxel, Carboplatin)</title>
          <description>Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Carboplatin: Given IV&#xD;
Docetaxel: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Sirolimus: Given PO</description>
        </group>
        <group group_id="E3">
          <title>Phase 1 Group</title>
          <description>Patients treated with docetaxel, carboplatin and sirolimus in the phase 1 component of study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 3 or greater neutropenia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bruce Montgomery</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-598-0860</phone>
      <email>rbmontgo@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

